- Collaboration revenue decreased to $7.2M from $13.8M in Q3 prior year, driven by lower Regeneron revenue.
- Net loss widened to $127.5M compared to $101.3M in Q3 2025.
- Pipeline updates include MAGNITUDE-2 trial enrollment completion and lonvo-z PDUFA target date of March 10, 2027.
Why is $NTLA moving today? · SEC 8-K archive
$NTLA SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $NTLA: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $NTLA filing catalyst
Why did $NTLA trigger an AI stock catalyst alert?
$NTLA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Intellia Therapeutics Reports Q3 Net Loss Widening to $127.5M as Revenue Declines. Key points: - Collaboration revenue decreased to $7.2M from $13.8M in Q3 prior year, driven by lower Regeneron revenue. - Net loss widened to $127.5M compared to $101.3M in Q3 2025. - Pipeline updates include MAGNITUDE-2 trial enrollment completion and lonvo-z PDUFA target date of March 10, 2027.
How did $NTLA stock react after the SEC filing?
After the SEC 8-K for $NTLA, observed market reaction: T0 price $12.31. Past moves do not guarantee future results.
Where can I get real-time $NTLA SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $NTLA via Telegram and the VIP Web Terminal from €10/month.